No recurrent MET fusions were identified, some of the fusion partners included HLA-DRB1-MET (lung cancer), CD47 (lung cancer), CAPZA2 (gastric cancer), AKAP9 (hepatobiliary cancer), CLIP2 (hepatobiliary cancer), and SLC25A19 (ovarian cancer). Here, MET is linked to ovarian cancer.